论文部分内容阅读
一种治疗偏头痛的新药即将开始全面临床试验。英国药理学家认为此种原型药物比目前用于治疗偏头痛的药物副作用少。据估计英国有500万人患有偏头痛。他们曾用以下药物治疗,如单纯止痛药、β-阻滞剂、麦角碱、神经介质拮抗剂5-羟色胺(5-HT)。没有一种药能解除偏头痛的发作。 Glaxo的Pat Humphrey医生认为原型药GR43175治疗偏头痛可能更有效。临床试验的初步报告指出,严重偏头痛发作的24名病人经静脉输入GR43175后,17人偏头痛迅速而完全
A new drug for migraine is about to begin a full-blown clinical trial. British pharmacologists think the prototype drug has fewer side effects than the drugs currently used to treat migraine. It is estimated that 5 million people in the UK have migraines. They have used the following drugs, such as simple analgesics, β-blockers, ergot, and neurotransmitter antagonist serotonin (5-HT). No drug can relieve the onset of migraine. Pat Humphrey, of Glaxo, believes the prototype drug GR43175 may be more effective in treating migraine. A preliminary clinical trial report noted that migraine was rapid and complete in 17 migraineurs after 24 intravenous GR243175s were administered to 24 patients with severe migraine attacks